Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas A Marciniak

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|September 17, 2020
The perils of data sharing, meta-analyses, and estimating cardiovascular riskThomas A Marciniak, Dan Atar, Victor Serebruany
Polish Archives of Internal Medicine|March 1, 2019
Predicting clinical outcomes after clopidogrel use: easier to postulate than to prove and implementVictor L Serebruany, Thomas A Marciniak, Dan Atar
International Journal of Clinical Practice|March 6, 2021
The FDA and PLATO Investigators death lists: Call for a matchVictor L Serebruany, Jean-Francois Tanguay, Thomas A Marciniak
European Heart Journal. Cardiovascular Pharmacotherapy|December 15, 2017
Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug AdministrationVictor L Serebruany, Moo Hyun Kim, Thomas A Marciniak
JAMA Internal Medicine|January 12, 2016
Drug Discontinuation and Follow-up Rates in Oral Antithrombotic TrialsThomas A Marciniak, Vasily Cherepanov, Elena Golukhova, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and UnderreportingVictor L Serebruany, Ales Tomek, Moo Hyun Kim, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 5, 2019
Ivabradine for heart failure: regulatory differences in Europe and United StatesThomas A Marciniak, Trygve S Hall, Dan Atar, et al.
American Journal of Therapeutics|September 15, 2023
Strokes and Transient Ischemic Attacks Occurrence During Annual Dual Antiplatelet TherapyVictor L Serebruany, Jean-Francois Tanguay, Milana L Gurvich, et al.
The American Journal of Medicine|February 24, 2023
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 YearVictor L Serebruany, Jean-Francois Tanguay, Milana L Gurvich, et al.
The American Journal of Medicine|February 6, 2017
Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial DeathsVictor L Serebruany, Seth D Fortmann, Vasily Cherepanov, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
European Heart Journal. Cardiovascular Pharmacotherapy|September 17, 2020
The perils of data sharing, meta-analyses, and estimating cardiovascular riskThomas A Marciniak, Dan Atar, Victor Serebruany
Polish Archives of Internal Medicine|March 1, 2019
Predicting clinical outcomes after clopidogrel use: easier to postulate than to prove and implementVictor L Serebruany, Thomas A Marciniak, Dan Atar
International Journal of Clinical Practice|March 6, 2021
The FDA and PLATO Investigators death lists: Call for a matchVictor L Serebruany, Jean-Francois Tanguay, Thomas A Marciniak
European Heart Journal. Cardiovascular Pharmacotherapy|December 15, 2017
Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug AdministrationVictor L Serebruany, Moo Hyun Kim, Thomas A Marciniak
JAMA Internal Medicine|January 12, 2016
Drug Discontinuation and Follow-up Rates in Oral Antithrombotic TrialsThomas A Marciniak, Vasily Cherepanov, Elena Golukhova, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Aspirin in the Food and Drug Administration Adverse Event Reporting System: Missing Demographics and UnderreportingVictor L Serebruany, Ales Tomek, Moo Hyun Kim, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|February 5, 2019
Ivabradine for heart failure: regulatory differences in Europe and United StatesThomas A Marciniak, Trygve S Hall, Dan Atar, et al.
American Journal of Therapeutics|September 15, 2023
Strokes and Transient Ischemic Attacks Occurrence During Annual Dual Antiplatelet TherapyVictor L Serebruany, Jean-Francois Tanguay, Milana L Gurvich, et al.
The American Journal of Medicine|February 24, 2023
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 YearVictor L Serebruany, Jean-Francois Tanguay, Milana L Gurvich, et al.
The American Journal of Medicine|February 6, 2017
Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial DeathsVictor L Serebruany, Seth D Fortmann, Vasily Cherepanov, et al.
Pageof 3